Welcome to Chemical Engineering at the University of Waterloo

Winning a pitch competition is never easy, but it becomes even more challenging when there is no prototype or product ready for market. Despite these obstacles, Capstone Group 4 defied the odds and won $12,000 to advance their project!

The project, called Direct-Li, won the Norman Esch Entrepreneurship Award for Capstone Design. The group proposed a more efficient and eco-friendly process for lithium extraction.

Through engineering innovation, Group 4 developed a two-stage process called direct lithium extraction (DLE). Group members Rachel Kumara, Sophie Campbell, Maeve Seto and Louise Tayzon utilized nanofiltration and ion pump separation to extract 90 per cent more lithium per litre of water in half the time compared to industry standards.

“We were delighted that we were successful in conveying our idea in a way that made the judges see value in something that we do not actually have, a solid prototype. Our ideas are based on simulations and models. We were shocked to win! We were just happy to be there and to be challenging ourselves, especially since we were the only all-women group in the competition!”

Professor Valerie Ward is part of a new global coalition to revolutionize vaccine production with disruptive health technology. The technology is designed to enable local vaccine production, reducing production time from nine days to just one day. A breakthrough that has the potential to save millions of lives and significantly lower the cost of vaccine production.

A research coalition led by the Centre for Process Innovation (CPI) received $2.8 million from the Coalition of Epidemic Preparedness Innovation (CEPI) to fund technology development to combat epidemics and pandemics. The aim is to make small transportable units to manufacture vaccines, making vaccines more accessible and better able to deal with local outbreaks.

Ward is working with researchers and industry partners in Brazil, the UK, and Canada to aid the world in responding more swiftly and equitably to future epidemics and pandemics. 

The grant focuses on developing technology to meet two specific goals. The first is rapid production of vaccines. The second is to decentralize manufacturing so it can be produced at different sites in smaller batches.

Researchers in the Department of Chemical Engineering have developed a new method for engineering bacteria that can be leveraged to improve biomedical applications such as drug delivery, cancer therapy, anti-inflammatory treatments, and vaccine development.

The international research group, led by Professor Yilan Liu, developed a process that enables bacteria to secrete bacterial membrane vesicles (BMVs). BMVs are nanosized bubble-shaped structures naturally released by bacteria. They have significant potential as tools for the development of a variety of therapeutics.  

Currently, the adoption of BMVs has been hindered by low production yields under natural conditions. The technique established by Liu resulted in a 140-fold increase in the secretion of BMVs.

"This advancement in bacterial engineering has the potential to be a transformative platform for next-generation vaccines, therapeutics, and nutrient delivery," says Liu. "This new process could profoundly impact global health by making biomedical treatments more efficient, accessible, and affordable."